v3.25.3
Other Operating Income And Expenses
 6 Months Ended
Jun. 30, 2025
Analysis of income and expense [abstract]  
Other Operating Income and Expenses
B.15. Other operating income and expenses
Other operating income
amounted to
€
533 million in the first half of 2025 (versus
€
563 million in the first half of 2024), and
Other operating expenses
to
€
2,476 million (
versus
€
 1,977 million in the first half of 2024).
Figures for the 2024 comparative period have been
re-presented
on a consistent basis to reflect the classification of Opella as a discontinued operation.
The main items included in
Other operating income
were: in the first half of 2025, (i) income from pharmaceutical partners of
€
87 million (versus
€
121 million in the first half of 2024), of which
€
70 million came from Regeneron (versus
€
96 million in the first half of 2024, see table below) and (ii) gains on disposals of assets and operations of
€
344 million, primarily on divestments of non strategic products (versus
€
319 million in the first half of 2024).
Other operating expenses
for the first half of 2025 included
€
2,331 million of expenses related to Regeneron (compared with
€
1,841 million in the first half of 2024), as shown in the table below.
 
(
€
 million)
   
June 30, 2025
(6 months)
    
June 30, 2024
(6 months)
  
Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance
   
 
(2,475
) 
  
 
(1,934
) 
Additional share of profit paid by Regeneron towards development costs
   
 
494
 
  
 
389
 
Reimbursement to Regeneron of selling expenses incurred
   
 
(346)
 
  
 
(292)
 
Total: Monoclonal Antibody Alliance
   
 
(2,327
) 
  
 
(1,837
) 
Other (mainly Zaltrap and Libtayo)
   
 
66
 
  
 
92
 
Other operating income/(expenses), net related to Regeneron
   
 
(2,261
) 
  
 
(1,745
) 
of which amount presented in “Other operating income”
   
 
70
 
  
 
96